Comparison 1. LNG 100 µg / EE 20 µg versus placebo.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Mean change in total lesion count	2	572	Mean Difference (IV, Fixed, 95% CI)	‐9.98 [‐16.51, ‐3.45]
2 Mean change in inflammatory lesion count	2	572	Mean Difference (IV, Fixed, 95% CI)	‐2.95 [‐4.97, ‐0.93]
3 Mean change in non‐inflammatory lesion count	2	572	Mean Difference (IV, Fixed, 95% CI)	‐6.75 [‐12.56, ‐0.94]
4 Clinician assessment of women with clear or almost clear lesions at cycle 6	2	571	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.56 [1.13, 2.18]
5 Participant self‐assessment of acne lesion improvement	2	572	Peto Odds Ratio (Peto, Fixed, 95% CI)	2.13 [1.47, 3.09]
6 Discontinuation due to non‐acne adverse event	1	350	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.54 [0.55, 4.31]
7 Discontinuation due to lack of acne improvement	1	350	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.88 [0.31, 2.47]